GLP-1 Market
LLY $1427.28 ▼ -0.7% NVO $40.65 ▼ -1.1% PFE $28.83 ▼ -2.1% VKTX $27.58 ▼ -3.0% KLRA $13.21 ▼ -8.1% GPCR $19.84 ▼ -5.3% RHHBY $60.57 • 0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Aripiprazole

Company
Otsuka Pharmaceutical Development & Commercialization, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
20 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

20 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 13, 2026

Find a Clinical Trial Near Me

See recruiting studies for Aripiprazole and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01246765

    National Pregnancy Registry for Psychiatric Medications

    Massachusetts General Hospital 5000 participants Est. completion 2033-12 1 site
    Other conditions: Pregnant Women, Psychotropic Drugs
    View official trial listing →
  • Recruiting NCT NCT02752542

    Personalized Indications for CBT and Antidepressants in Treating Depression

    Not yet reported Nova Scotia Health Authority 80 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Major Depressive Disorder, Persistent Depressive Disorder
    View official trial listing →
  • Recruiting NCT NCT04539951

    Pragmatic Trial of Obsessive-compulsive Disorder

    Not yet reported Shanghai Mental Health Center 1600 participants Est. completion 2028-12-31 1 site
    Other conditions: Obsessive-Compulsive Disorder
    View official trial listing →
  • Recruiting NCT NCT04789915

    Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

    Not yet reported Bjorn H. Ebdrup 46 participants Est. completion 2026-12-31 1 site
    Other conditions: Psychosis, Negative Symptoms With Primary Psychotic Disorder
    View official trial listing →
  • Recruiting NCT NCT05814640

    Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

    Not yet reported, Not yet reported First Affiliated Hospital of Chongqing Medical University 520 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Depression, Sequestra
    View official trial listing →
  • Recruiting NCT NCT05942716

    Serotonin Control of Impulsivity in Tourette Disorder

    Not yet reported Hospices Civils de Lyon 25 participants Est. completion 2028-09-24 2 sites Stand-alone
    Other conditions: Tourette Disorder
    View official trial listing →
  • Recruiting NCT NCT06049953

    Maternal And Infant Antipsychotic Study

    Icahn School of Medicine at Mount Sinai 74 participants Est. completion 2028-01-01 1 site
    Other conditions: Antipsychotics, Pregnancy
    View official trial listing →
  • Recruiting NCT NCT06054321

    Psychopharmacotherapy for Depressive Patients

    Not yet reported Chonnam National University Hospital 400 participants Est. completion 2030-12-31 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Recruiting NCT NCT06467474

    Psychoeducational Group for Depression

    Not yet reported Ricardo Alberto Moreno, M.D., Ph.D. 338 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Major Depressive Disorder (MDD
    View official trial listing →
  • Recruiting NCT NCT06482554

    Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

    Not yet reported Louisiana State University Health Sciences Center Shreveport 80 participants Est. completion 2026-12 1 site
    Other conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
    View official trial listing →
  • Recruiting NCT NCT06581302

    Magnetic Seizure Therapy for Psychotic Disorders

    Not yet reported Shanghai Jiao Tong University School of Medicine 50 participants Est. completion 2025-12-30 2 sites
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Recruiting NCT NCT06591091

    Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

    Not yet reported University of Illinois Chicago 80 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Depression
    View official trial listing →
  • Recruiting NCT NCT06613334

    Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses

    Not yet reported Centre Hospitalier St Anne 200 participants Est. completion 2027-10 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT06969755

    Biomarkers to Enhance Early Schizophrenia Treatment

    Not yet reported Northwell Health 180 participants Est. completion 2030-07-30 5 sites
    Other conditions: Schizophenia Disorder
    View official trial listing →
  • Recruiting NCT NCT07215884

    Dopamine and Sensorimotor Function in Stuttering

    Not yet reported University of California, San Francisco 25 participants Est. completion 2027-08-30 1 site
    Other conditions: Stuttering, Adult
    View official trial listing →
  • Recruiting NCT NCT07483294

    Cerebellum-based Imaging Neural Markers for Antipsychotic Response

    Not yet reported Northwell Health 120 participants Est. completion 2030-06-01 1 site Stand-alone
    Other conditions: Psychosis; Acute
    View official trial listing →
  • Recruiting NCT NCT07565428

    Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

    Not yet reported Minerva Neurosciences 380 participants Est. completion 2028-12 13 sites Stand-alone
    Other conditions: Negative Symptoms of Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT07703670

    MicroRNAs as Biomarkers in First Episode Schizophrenia

    Not yet reported Northwell Health 160 participants Est. completion 2031-05-01 1 site Stand-alone
    Other conditions: Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
    View official trial listing →
  • Recruiting NCT NCT07858565

    Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder

    Bosnalijek D.D 500 participants Est. completion 2027-05 1 site
    Other conditions: Schizophrenia, Bipolar Affective Disorder
    View official trial listing →
  • Recruiting NCT NCT07918222

    Sequential Treatment Approaches for Treatment-Resistant Schizophrenia

    Not yet reported Shanghai Mental Health Center 300 participants Est. completion 2030-12-01 1 site Stand-alone
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Completed NCT NCT00036101

    Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-01 27 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00036114

    Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-08 41 sites
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT00036127

    Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

    Not yet reported, Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-01 16 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00036348

    Study of Aripiprazole in Patients With a History of Bipolar Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-06 19 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00036361

    Broad Effectiveness: Study With Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 444 participants Est. completion 2003-01 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00041678

    Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-03 6 sites
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT00044655

    Switching Medication to Treat Schizophrenia

    Not yet reported Icahn School of Medicine at Mount Sinai 219 participants Est. completion 2009-03
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00046384

    Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2003-04 14 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00080314

    Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 400 participants Est. completion 2006-10 28 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00080327

    Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 370 participants Est. completion 2004-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00082199

    Study of Aripiprazole in Subjects With Alcoholism

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 400 participants Est. completion 2005-08 14 sites
    Other conditions: Alcoholism
    View official trial listing →
  • Completed NCT NCT00088049

    Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

    Not yet reported Eli Lilly and Company 560 participants Est. completion 2007-07 24 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT00089440

    Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

    Not yet reported National Institute on Drug Abuse (NIDA) 17 participants Est. completion 2005-03 2 sites
    Other conditions: Amphetamine-Related Disorders
    View official trial listing →
  • Completed NCT NCT00094432

    A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 650 participants Est. completion 2006-11 40 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00095511

    Aripiprazole in Patients With Acute Mania

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 615 participants Est. completion 2007-05 38 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00095524

    Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 300 participants Est. completion 2006-08 32 sites
    Other conditions: Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
    View official trial listing →
  • Completed NCT NCT00095719

    Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 125 participants Est. completion 2005-03 14 sites
    Other conditions: Dementia, Alzheimer's Disease
    View official trial listing →
  • Completed NCT NCT00095745

    A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1002 participants Est. completion 2007-11 58 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00095758

    A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1151 participants Est. completion 2006-12-01 28 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00095810

    Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 50 participants Est. completion 2004-09 1 site Stand-alone
    Other conditions: Parkinson's Disease, Psychoses
    View official trial listing →
  • Completed NCT NCT00095823

    A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1200 participants Est. completion 2006-08 20 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00097266

    Study of Aripiprazole in Patients With Acute Bipolar Mania

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 615 participants Est. completion 2007-01 45 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00101569

    Aripiprazole Oral Acceptability Trial

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 59 participants Est. completion 2005-03 7 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00102063

    Aripiprazole in Adolescents With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 302 participants Est. completion 2006-08 55 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00102479

    Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 21 participants Est. completion 2005-07-01 Stand-alone
    Other conditions: Schizophrenia, Mania
    View official trial listing →
  • Completed NCT NCT00102518

    Aripiprazole Open-Label, Safety and Tolerability Study

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 325 participants Est. completion 2007-02 50 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00103571

    Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 600 participants Est. completion 2006-08 5 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00105196

    A Study of Aripiprazole in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 349 participants Est. completion 2008-03 34 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00110461

    Aripiprazole in Children and Adolescents With Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 296 participants Est. completion 2007-02 53 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00116259

    Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)

    Not yet reported Federal University of Rio Grande do Sul 50 participants Est. completion 2008-02 1 site
    Other conditions: Bipolar Disorder, Attention Deficit Hyperactivity Disorder
    View official trial listing →
  • Completed NCT NCT00149734

    Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

    Not yet reported University of Colorado, Denver 8 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00167817

    Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study

    Not yet reported Veterans Medical Research Foundation 15 participants Est. completion 2005-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00169949

    Aripiprazole Treatment of the Prodrome

    Not yet reported Northwell Health 30 participants Est. completion 2006-05 1 site
    Other conditions: Prodromal Schizophrenia, Prodromal Psychosis
    View official trial listing →
  • Completed NCT NCT00174876

    Aripiprazole as Augmentation for TRD

    Not yet reported State University of New York - Upstate Medical University 20 participants Est. completion 2005-05 1 site
    Other conditions: Depression
    View official trial listing →
  • Completed NCT NCT00177008

    Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

    Not yet reported University of Medicine and Dentistry of New Jersey 18 participants Est. completion 2007-01 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
    View official trial listing →
  • Completed NCT NCT00177164

    Risperdal Consta for Bipolar Disorder

    Not yet reported University of Pittsburgh 50 participants Est. completion 2009-12 4 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00181779

    Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2006-12 1 site
    Other conditions: Bipolar Disorder, Mania
    View official trial listing →
  • Completed NCT NCT00183235

    Aripiprazole Effects on Alcohol Reactivity and Consumption

    Not yet reported Medical University of South Carolina 30 participants Est. completion 2006-02 1 site
    Alcohol use disorder
    View official trial listing →
  • Completed NCT NCT00194012

    Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

    Not yet reported University Hospitals Cleveland Medical Center 62 participants Est. completion 2012-06 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00194038

    Aripiprazole in Late Life Bipolar Disorder

    Not yet reported University Hospitals Cleveland Medical Center 20 participants Est. completion 2006-06 Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00194077

    Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

    Not yet reported University Hospitals Cleveland Medical Center 60 participants Est. completion 2011-01 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00198055

    A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

    Not yet reported Indiana University 25 participants Est. completion 2007-09 1 site Stand-alone
    Other conditions: Asperger's Disorder, Pervasive Developmental Disorder
    View official trial listing →
  • Completed NCT NCT00198107

    Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

    Not yet reported Indiana University 81 participants Est. completion 2011-09 1 site
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT00198198

    Aripiprazole Treatment of Bipolar Depression

    Not yet reported Indiana University 10 participants Est. completion 2006-11 1 site
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00202007

    Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

    Not yet reported Otsuka Beijing Research Institute 240 participants Est. completion 2005-07 6 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00205660

    Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

    Not yet reported Washington University School of Medicine 51 participants Est. completion 2009-08 1 site
    Type 2 diabetes Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00205699

    Metabolic Effects of Antipsychotics in Children

    Not yet reported Washington University School of Medicine 144 participants Est. completion 2011-07 1 site
    Other conditions: Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00208169

    Abilify Therapy for Reducing Comorbid Substance Abuse

    Not yet reported Creighton University 30 participants Est. completion 2007-06 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
    View official trial listing →
  • Completed NCT NCT00208533

    Aripiprazole in Children With Autism: A Pilot Study

    Not yet reported Drexel University College of Medicine 11 participants Est. completion 2011-11-16 1 site
    Other conditions: Autism
    View official trial listing →
  • Terminated NCT NCT00209027

    The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

    Not yet reported Emory University 20 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00211302

    Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

    Not yet reported Louisiana State University Health Sciences Center Shreveport 8 participants Est. completion 2006-02 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Terminated NCT NCT00211380

    Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

    Not yet reported Louisiana State University Health Sciences Center Shreveport 8 participants Est. completion 2006-02 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00216476

    A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

    Not yet reported Janssen-Cilag International NV 753 participants Est. completion 2007-11 96 sites
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00216723

    Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

    Korea Otsuka Pharmaceutical Co., Ltd. 3000 participants Est. completion 2009-12 2 sites
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00220636

    Abilify as an Adjunctive Treatment for Refractory Depression

    Not yet reported St. Luke's-Roosevelt Hospital Center 15 participants Est. completion 2008-01 1 site Stand-alone
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Completed NCT NCT00221416

    An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder

    Not yet reported University of Cincinnati 30 participants Est. completion 2008-12
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00221962

    Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

    Not yet reported University Hospitals Cleveland Medical Center 23 participants Est. completion 2007-04 1 site
    Other conditions: Attention Deficit Hyperactivity Disorder
    View official trial listing →
  • Completed NCT NCT00222833

    The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

    Not yet reported University of Pittsburgh 30 participants Est. completion 2005-12 1 site
    Cardiovascular disease Other conditions: Overweight, Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT00223418

    Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

    Not yet reported The University of Texas Health Science Center at San Antonio 43 participants Est. completion 2007-06 1 site
    Other conditions: Schizophenia Disorder, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00223496

    12- Week Open Label Treatment of Refractory Bipolar Depression

    Not yet reported The University of Texas Health Science Center at San Antonio 32 participants Est. completion 2009-09 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00224822

    The Effects of Aripiprazole on Patients With Metabolic Syndrome

    Not yet reported New Mexico VA Healthcare System 27 participants Est. completion 2007-03 1 site
    Metabolic syndrome Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00226317

    Aripiprazole in the Treatment of Bipolar Depression

    Not yet reported Cambridge Health Alliance 20 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00232687

    A Switch Study of BMS-337039 in Schizophrenic Out-patients

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 450 participants Est. completion 2007-04-01 72 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00237874

    Aripiprazole Treatment of Prodromal Patients

    Not yet reported, Not yet reported Yale University 15 participants Est. completion 2007-02 2 sites
    Other conditions: Schizophrenia, Psychosis
    View official trial listing →
  • Completed NCT NCT00237913

    Schizophrenia Trial of Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 700 participants Est. completion 2005-08 33 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00237939

    A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1200 participants Est. completion 2006-11 20 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00239356

    Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 119 participants Est. completion 2012-10 20 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00241176

    Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

    Not yet reported NYU Langone Health 11 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Tourette's Syndrome, Tic Disorders
    View official trial listing →
  • Completed NCT NCT00245206

    Side Effects of Newer Antipsychotics in Older Adults

    Not yet reported Veterans Medical Research Foundation 406 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Schizophrenia, Alzheimer's Disease, Dementia
    View official trial listing →
  • Completed NCT NCT00250705

    Trial of Aripiprazole in the Treatment of CD in Adolescents

    Not yet reported University of Iowa 12 participants Est. completion 2009-03-23 1 site
    Other conditions: Conduct Disorder
    View official trial listing →
  • Completed NCT NCT00257972

    Study of Aripiprazole in Patients With Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 400 participants Est. completion 2007-12 90 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00261443

    A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1270 participants Est. completion 2009-10 83 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00276874

    Aripiprazole to Reduce Cocaine Relapse

    Not yet reported Craig Rush 41 participants Est. completion 2012-01 1 site Stand-alone
    Other conditions: Cocaine-Related Disorders
    View official trial listing →
  • Withdrawn NCT NCT00276978

    Aripiprazole Augmentation Therapy in Treatment-resistant Depression

    Not yet reported University Hospital Freiburg Est. completion 2009-11 1 site Stand-alone
    Other conditions: Therapy-resistant Depression
    View official trial listing →
  • Completed NCT NCT00277212

    A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1169 participants Est. completion 2009-07-01 66 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT00279409

    Treatment of Children With ADHD Who do Not Fully Respond to Stimulants

    Not yet reported New York State Psychiatric Institute 10 participants Est. completion 2009-02 1 site
    Other conditions: Attention Deficit Hyperactivity Disorder
    View official trial listing →
  • Terminated NCT NCT00282139

    Aripiprazole in the Treatment of Tourette's Syndrome

    Not yet reported University of Florida 40 participants Est. completion 2006-10 1 site
    Other conditions: Tourette's Syndrome
    View official trial listing →
  • Completed NCT NCT00283179

    Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

    Not yet reported Taiwan Otsuka Pharm. Co., Ltd 83 participants Est. completion 2004-12 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Terminated NCT NCT00288353

    Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

    Not yet reported Northwestern University 48 participants Est. completion 2008-12 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00288366

    Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

    Not yet reported Northwestern University 49 participants Est. completion 2008-12 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00292409

    A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 400 participants Est. completion 2007-11
    Other conditions: Schizophrenia and Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00299702

    Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 355 participants Est. completion 2009-01
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00300846

    A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 200 participants Est. completion 2007-07 57 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00304616

    SWitching to Abilify Trial (SWAT)

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 500 participants Est. completion 2007-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00304655

    Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 300 participants Est. completion 2007-10 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00305370

    Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD

    Not yet reported Federal University of Rio Grande do Sul 20 participants Est. completion 2008-03 1 site
    Other conditions: Bipolar Disorder, Attention Deficit Hyperactivity Disorder
    View official trial listing →
  • Completed NCT NCT00308074

    An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders

    Not yet reported Cambridge Health Alliance 14 participants Est. completion 2009-02 1 site Stand-alone
    Other conditions: Autism, Asperger's Disorder, Pervasive Developmental Disorder
    View official trial listing →
  • Completed NCT NCT00312598

    Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine

    University of North Carolina, Chapel Hill 30 participants Est. completion 2010-04
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
    View official trial listing →
  • Completed NCT NCT00320671

    Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

    Not yet reported Northwell Health 198 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00321516

    Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 20 participants Est. completion 2007-02 4 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00325689

    Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 323 participants Est. completion 2007-10 48 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00328367

    Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

    Not yet reported Seoul National University Hospital 61 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00329810

    Effect on Cognitive Function of a Treatment With Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 500 participants Est. completion 2006-03 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00330863

    Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

    Not yet reported Northwell Health 357 participants Est. completion 2011-01 8 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00332241

    Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 98 participants Est. completion 2008-04-01 9 sites Stand-alone
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT00337571

    Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 218 participants Est. completion 2008-06-01 31 sites Stand-alone
    Other conditions: Behavioral Symptoms, Autistic Disorder
    View official trial listing →
  • Withdrawn NCT NCT00338273

    A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2007-11 8 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00345033

    Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

    Not yet reported Massachusetts General Hospital 38 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Schizophrenia, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00347425

    Switch Study of Existing Atypical Antipsychotics to Bifeprunox

    Not yet reported Solvay Pharmaceuticals 286 participants Est. completion 2008-02 122 sites
    Other conditions: Schizophrenia and Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00351936

    A Placebo-Controlled, Cross-Over Trial of Aripiprazole

    Not yet reported North Suffolk Mental Health Association 16 participants Est. completion 2007-07 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT00352339

    The New Strategy for Pharmacological Treatment in People With Schizophrenia

    Not yet reported Inje University 90 participants Est. completion 2010-12 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00361790

    Aripiprazole and Lexapro Drug Interaction Study

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 25 participants Est. completion 2006-11 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00362271

    Aripiprazole and Effexor XR Drug Interaction Study

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 38 participants Est. completion 2006-09 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00363337

    A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

    Not yet reported Lindner Center of HOPE 31 participants Est. completion 2009-03 1 site
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00365339

    Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

    Not yet reported Bristol-Myers Squibb 40 participants Est. completion 2006-06 1 site
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT00365859

    Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 330 participants Est. completion 2009-06-01 55 sites Stand-alone
    Other conditions: Autistic Disorder, Behavioral Symptoms
    View official trial listing →
  • Completed NCT NCT00373880

    Effects of Aripiprazole on Cocaine Craving and Self-Administration

    Not yet reported New York State Psychiatric Institute 26 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Cocaine Abuse
    View official trial listing →
  • Completed NCT NCT00374348

    Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)

    Not yet reported Jamaica Hospital Medical Center 10 participants Est. completion 2008-05 1 site
    Other conditions: Schizophrenia OCD, Obsessive Compulsive Disorder
    View official trial listing →
  • Completed NCT NCT00392197

    Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 111 participants Est. completion 2010-03 5 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00393328

    Bioequivalence Study of Atazanavir 300 mg Capsule

    Not yet reported Bristol-Myers Squibb 46 participants Est. completion 2006-12 1 site
    Other conditions: HIV Infections
    View official trial listing →
  • Status unknown NCT NCT00395915

    Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

    Not yet reported Universita di Verona 106 participants Est. completion 2009-12 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00420459

    A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

    Not yet reported Indiana University 12 participants Est. completion 2010-03 1 site Stand-alone
    Other conditions: Fragile X Syndrome
    View official trial listing →
  • Completed NCT NCT00423878

    Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

    Not yet reported National Institute of Mental Health (NIMH) 215 participants Est. completion 2010-03 28 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00438386

    Aripiprazole for the Treatment of Refractory Anxiety

    Not yet reported Massachusetts General Hospital Est. completion 2007-06 1 site
    Other conditions: Generalized Anxiety Disorder, Panic Disorder
    View official trial listing →
  • Terminated NCT NCT00439634

    Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

    Not yet reported Sanofi 873 participants Est. completion 2009-09 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00440713

    Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms

    Not yet reported Federal University of São Paulo 40 participants Est. completion 2006-03
    Other conditions: Posttraumatic Stress Disorder
    View official trial listing →
  • Completed NCT NCT00448630

    An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

    Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 328 participants Est. completion 2008-07-30 47 sites
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00466310

    Metabolic Signatures and Biomarkers in Schizophrenia

    Not yet reported Duke University 71 participants Est. completion 2011-01 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00468130

    Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

    Not yet reported University of Medicine and Dentistry of New Jersey 13 participants Est. completion 2009-11 1 site Stand-alone
    Other conditions: Autism
    View official trial listing →
  • Status unknown NCT NCT00468533

    The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial

    Not yet reported Yu-Li Hospital 50 participants Est. completion 2007-07 1 site
    Metabolic syndrome
    View official trial listing →
  • Completed NCT NCT00484471

    ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

    Not yet reported Korea Otsuka International Asia Arab 127 participants Est. completion 2012-11 13 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT00488891

    The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia

    Ortho-McNeil Janssen Scientific Affairs, LLC 43 participants Est. completion 2007-10
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00489866

    Aripiprazole Augmentation of Antidepressants in PTSD

    Not yet reported Durham VA Medical Center 14 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: PTSD
    View official trial listing →
  • Completed NCT NCT00497055

    Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals

    Not yet reported San Francisco Department of Public Health 90 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Substance Abuse, HIV Infections
    View official trial listing →
  • Terminated NCT NCT00508157

    A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 125 participants Est. completion 2009-03-01 30 sites Stand-alone
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00509067

    Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

    Not yet reported Georgetown University 43 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00520650

    Health Evaluation of Abilify Long-term Therapy

    Not yet reported Taiwan Otsuka Pharm. Co., Ltd 245 participants Est. completion 2009-04 9 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00528359

    β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain 36 participants Est. completion 2007-02 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00531518

    Early Detection and Intervention for the Prevention of Psychosis

    Not yet reported MaineHealth 292 participants Est. completion 2013-09 6 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
    View official trial listing →
  • Status unknown NCT NCT00541502

    Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder

    Genovate Biotechnology Co., Ltd., Est. completion 2008-10
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Status unknown NCT NCT00541554

    Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia

    Not yet reported Genovate Biotechnology Co., Ltd., Est. completion 2009-02
    Other conditions: Hyperprolactinemia, Weight Gain, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT00545142

    Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 280 participants Est. completion 2010-06 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00545467

    Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents

    Not yet reported National Taiwan University Hospital 79 participants Est. completion 2009-07 1 site
    Other conditions: DSM-IV Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00545675

    Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 146 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00556140

    The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

    Not yet reported Massachusetts General Hospital 16 participants Est. completion 2008-01 1 site Stand-alone
    Other conditions: Psychotic Depression
    View official trial listing →
  • Status unknown NCT NCT00567099

    Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

    Not yet reported New Mexico VA Healthcare System 20 participants Est. completion 2008-09 1 site
    Other conditions: Schizophrenia, Sensory Gating
    View official trial listing →
  • Status unknown NCT NCT00569764

    Effect on Metabolic Parameters of Abilify in SPR

    Seoul National Hospital 100 participants Est. completion 2009-10 2 sites
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00573716

    Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents

    Creighton University 60 participants Est. completion 2009-10 1 site
    Other conditions: Psychiatry
    View official trial listing →
  • Completed NCT NCT00580125

    Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

    Not yet reported Pfizer 164 participants Est. completion 2008-09 26 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00592683

    Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2010-04 1 site
    Other conditions: Pediatric Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00606177

    A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 99 participants Est. completion 2010-11 12 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00606229

    A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 41 participants Est. completion 2010-11 5 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00606281

    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 258 participants Est. completion 2010-11 12 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00606320

    A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 59 participants Est. completion 2010-11 12 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00608543

    Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

    Not yet reported University of Texas Southwestern Medical Center 17 participants Est. completion 2009-01 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Terminated NCT NCT00617058

    Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

    Not yet reported University of North Carolina, Chapel Hill 1 participants Est. completion 2010-09 1 site
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00619190

    Study of Aripiprazole to Treat Children and Adolescents With Autism

    Not yet reported University of North Carolina, Chapel Hill 30 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT00634348

    A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

    Not yet reported Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 256 participants Est. completion 2005-03 41 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00665366

    Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 493 participants Est. completion 2011-10 73 sites
    Other conditions: Bipolar Disorder Mania
    View official trial listing →
  • Terminated NCT NCT00665444

    Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

    Not yet reported University of Pittsburgh 3 participants Est. completion 2009-08 1 site Stand-alone
    Metabolic syndrome Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00667745

    Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

    Not yet reported National Institute of Mental Health (NIMH) 283 participants Est. completion 2010-03 6 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00667875

    An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence

    Not yet reported Medical University of South Carolina 65 participants Est. completion 2011-05 1 site
    Alcohol use disorder
    View official trial listing →
  • Completed NCT NCT00683852

    A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

    Not yet reported Massachusetts General Hospital 225 participants Est. completion 2009-09 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00685334

    Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

    Not yet reported New York State Psychiatric Institute 22 participants Est. completion 2006-09 2 sites
    Other conditions: Eating Disorders
    View official trial listing →
  • Completed NCT NCT00689559

    Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects

    Not yet reported AstraZeneca 52 participants Est. completion 2009-04 1 site Stand-alone
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Completed NCT NCT00704860

    Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism

    Not yet reported University of Ottawa 27 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Major Depression
    View official trial listing →
  • Completed NCT NCT00705783

    Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 843 participants Est. completion 2011-02 110 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00706589

    Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 61 participants Est. completion 2010-04 6 sites Stand-alone
    Other conditions: Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
    View official trial listing →
  • Completed NCT NCT00706654

    Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 937 participants Est. completion 2012-08-01 98 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00712270

    Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

    Not yet reported Kettering Health Network 21 participants Est. completion 2010-11 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00712686

    Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 690 participants Est. completion 2003-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT00728312

    Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial

    Not yet reported US Department of Veterans Affairs Est. completion 2010-04
    Other conditions: Methamphetamine Dependence
    View official trial listing →
  • Completed NCT NCT00731549

    Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 1081 participants Est. completion 2013-11 214 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT00737256

    A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

    Not yet reported Paul Saenger 44 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Schizophrenia, Cocaine Dependence
    View official trial listing →
  • Terminated NCT NCT00746252

    Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

    Not yet reported University of Maryland, Baltimore 5 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Status unknown NCT NCT00752960

    DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

    Genomas, Inc 1000 participants Est. completion 2009-12 2 sites
    Other conditions: Psychoses
    View official trial listing →
  • Completed NCT NCT00780702

    Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients

    Not yet reported National Institute on Drug Abuse (NIDA) 41 participants Est. completion 2013-04-16 1 site Stand-alone
    Other conditions: Cocaine Dependence, Cocaine-Related Disorders, Opioid-Related Disorders
    View official trial listing →
  • Completed NCT NCT00802100

    Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

    Not yet reported National Institute of Mental Health (NIMH) 21 participants Est. completion 2009-10 13 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00806234

    Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

    Not yet reported Johns Hopkins University 127 participants Est. completion 2014-03 4 sites Stand-alone
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Status unknown NCT NCT00837707

    Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

    Not yet reported Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan 25 participants Est. completion 2010-02 1 site
    Other conditions: Dyskinesia, Drug-Induced
    View official trial listing →
  • Completed NCT NCT00845026

    A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

    Not yet reported Denovo Biopharma LLC 261 participants Est. completion 2010-12 23 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00845988

    Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

    Not yet reported Seoul National University Hospital 28 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Bipolar Disorders, Metabolic Complication
    View official trial listing →
  • Terminated NCT NCT00857818

    Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 64 participants Est. completion 2010-03 14 sites Stand-alone
    Metabolic syndrome Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00870727

    Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders

    Not yet reported Indiana University 33 participants Est. completion 2015-05 1 site Stand-alone
    Other conditions: Pervasive Developmental Disorder
    View official trial listing →
  • Completed NCT NCT00873795

    Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression

    Not yet reported Chimei Medical Center 41 participants Est. completion 2009-03 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00876343

    Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 586 participants Est. completion 2012-07 8 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00882362

    Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 155 participants Est. completion 2012-07 8 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00884884

    Aripiprazole and Topiramate on Free-Choice Alcohol Use

    Not yet reported, Not yet reported National Institute on Alcohol Abuse and Alcoholism (NIAAA) 90 participants Est. completion 2015-10 1 site Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Completed NCT NCT00892047

    Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

    Not yet reported University of Pittsburgh 468 participants Est. completion 2014-09 3 sites Stand-alone
    Other conditions: Depression
    View official trial listing →
  • Completed NCT NCT00895921

    Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

    Not yet reported Veterans Medical Research Foundation 30 participants Est. completion 2010-06 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT00905307

    Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 459 participants Est. completion 2010-11 73 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT00910780

    Metabolic Effects of Antipsychotic Substitution in Children

    Not yet reported, Not yet reported Washington University School of Medicine Est. completion 2009-11
    Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT00926835

    Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

    Not yet reported Ministry of Health & Welfare, Korea 692 participants Est. completion 2015-07 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00947154

    Trial of Aripiprazole in Trichotillomania

    Not yet reported Stanford University 12 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Trichotillomania
    View official trial listing →
  • Completed NCT NCT00953745

    Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

    Not yet reported Washington University School of Medicine 43 participants Est. completion 2012-12 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00956189

    Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

    Not yet reported National Taiwan University Hospital 132 participants Est. completion 2012-10 3 sites Stand-alone
    Metabolic syndrome
    View official trial listing →
  • Status unknown NCT NCT01000402

    Juvenile Bipolar Disorder Outpatient Program

    Not yet reported Federal University of Rio Grande do Sul 150 participants Est. completion 2014-11 1 site
    Other conditions: Bipolar Disorder, Attention Deficit Disorder With Hyperactivity
    View official trial listing →
  • Completed NCT NCT01001702

    Oral Aripiprazole Open-Label Rollover Study

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 85 participants Est. completion 2012-07 15 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01009047

    An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

    Not yet reported Janssen Research & Development, LLC 228 participants Est. completion 2012-06 41 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT01016145

    Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm

    Not yet reported University of Sao Paulo 126 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Schizophrenia or Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01026584

    Efficacy and Safety of Aripiprazole in First Episode Psychosis

    Not yet reported Chonbuk National University Hospital 55 participants Est. completion 2012-02 13 sites
    Other conditions: First Episode Psychosis
    View official trial listing →
  • Completed NCT NCT01028820

    FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

    Not yet reported University of North Carolina, Chapel Hill 13 participants Est. completion 2011-01 2 sites Stand-alone
    Other conditions: Autism Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT01043250

    Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

    Samsung Medical Center 81 participants Est. completion 2010-12 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Status unknown NCT NCT01047215

    Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine

    Not yet reported Taichung Veterans General Hospital 120 participants Est. completion 2010-06 1 site
    Other conditions: Schizophrenia, Bipolar
    View official trial listing →
  • Completed NCT NCT01052103

    A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

    Not yet reported Denovo Biopharma LLC 167 participants Est. completion 2012-06 9 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01052389

    Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia

    Not yet reported Mario Negri Institute for Pharmacological Research 300 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01057329

    Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

    Medical University of Vienna 200 participants Est. completion 2019-03-05 1 site
    Obstructive sleep apnea Other conditions: Depression, ADHD
    View official trial listing →
  • Status unknown NCT NCT01057849

    Standard Comprehensive Intervention to Treat First-episode Schizophrenia

    Not yet reported Peking University 600 participants 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT01075373

    A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations

    National Taiwan University Hospital 360 participants Est. completion 2010-11 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT01082848

    ARIpiprazole in Anorexia NErvosa

    Not yet reported Juan A. Arnaiz 60 participants Est. completion 2013-03 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT01085383

    Aripiprazole and Prolactin Study

    Not yet reported University of Oxford 15 participants Est. completion 2014-12 1 site
    Other conditions: Hyperprolactinemia
    View official trial listing →
  • Completed NCT NCT01104766

    Safety and Efficacy of Cariprazine in Patients With Schizophrenia

    Not yet reported Forest Laboratories 617 participants Est. completion 2011-12-20 58 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01109147

    Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients

    Not yet reported Qualissima 67 participants Est. completion 2013-05 2 sites
    Other conditions: Schizophrenia, Undifferentiated Type
    View official trial listing →
  • Terminated NCT NCT01111539

    Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 211 participants Est. completion 2011-09-20 62 sites Stand-alone
    Other conditions: Major Depressive Disorder (MDD)
    View official trial listing →
  • Terminated NCT NCT01111552

    Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 237 participants Est. completion 2011-09-27 60 sites
    Other conditions: Major Depressive Disorder (MDD)
    View official trial listing →
  • Terminated NCT NCT01111565

    Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 137 participants Est. completion 2011-09-01 53 sites Stand-alone
    Other conditions: Major Depressive Disorder (MDD)
    View official trial listing →
  • Completed NCT NCT01119014

    Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis

    Not yet reported Anne Katrine Pagsberg 300 participants Est. completion 2015-07 9 sites Stand-alone
    Other conditions: Psychosis
    View official trial listing →
  • Terminated NCT NCT01122927

    Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 524 participants Est. completion 2014-09 101 sites Stand-alone
    Other conditions: Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
    View official trial listing →
  • Terminated NCT NCT01123707

    To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 173 participants Est. completion 2011-09-27 Stand-alone
    Other conditions: Major Depressive Disorder (MDD)
    View official trial listing →
  • Terminated NCT NCT01129674

    A Long-Term, Open-Label, Study on Schizophrenia

    Not yet reported, Not yet reported Denovo Biopharma LLC 560 participants Est. completion 2012-10 81 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01129882

    An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 709 participants Est. completion 2018-12-06 157 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01149655

    Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 252 participants Est. completion 2013-12 52 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01154829

    Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

    Not yet reported University of Copenhagen 136 participants Est. completion 2016-05 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT01155544

    Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole

    Not yet reported Northwell Health Est. completion 2014-06 2 sites
    Other conditions: Substance Abuse, Substance Dependence
    View official trial listing →
  • Completed NCT NCT01157351

    15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

    Not yet reported Janssen Scientific Affairs, LLC 450 participants Est. completion 2013-12 56 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01161277

    Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning

    Not yet reported Oslo University Hospital 54 participants Est. completion 2011-06 1 site
    Other conditions: Psychosis, Schizophrenia
    View official trial listing →
  • Completed NCT NCT01164059

    Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

    Not yet reported University of Bremen 149 participants Est. completion 2014-03 18 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01185418

    Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer

    Chonbuk National University Hospital 80 participants Est. completion 2009-07 1 site
    Other conditions: Normal Volunteers
    View official trial listing →
  • Completed NCT NCT01188668

    Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

    Not yet reported Pfizer 38 participants Est. completion 2010-10 2 sites Stand-alone
    Other conditions: Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
    View official trial listing →
  • Withdrawn NCT NCT01193166

    Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

    Not yet reported Ortho-McNeil Janssen Scientific Affairs, LLC Est. completion 2012-09
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01207414

    Switching to Iloperidone From Other Antipsychotics in Schizophrenia

    Not yet reported Novartis 501 participants Est. completion 2012-01 59 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01227668

    Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 215 participants Est. completion 2012-06-20 38 sites Stand-alone
    Other conditions: Irritability Associated With Autistic Disorder
    View official trial listing →
  • Completed NCT NCT01231074

    Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

    Not yet reported Nationwide Children's Hospital 96 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Obesity, Weight Gain, Psychotropic Induced Weight Gain
    View official trial listing →
  • Completed NCT NCT01284218

    Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

    Otsuka Pharmaceutical Development & Commercialization, Inc. 23514 participants Est. completion 2011-12
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Completed NCT NCT01292057

    Aripiprazole Effects on Alcohol Drinking and Craving

    Not yet reported Medical University of South Carolina 99 participants Est. completion 2015-12 1 site
    Alcohol use disorder
    View official trial listing →
  • Terminated NCT NCT01305707

    Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

    Not yet reported Hospital Universitari de Bellvitge 104 participants Est. completion 2014-07 3 sites
    Other conditions: Depression
    View official trial listing →
  • Completed NCT NCT01323205

    Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    Not yet reported Janssen Research & Development, LLC 100 participants Est. completion 2012-12 20 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01328093

    A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

    Not yet reported Denovo Biopharma LLC 678 participants Est. completion 2012-10 51 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01333072

    Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

    Not yet reported Medical University of South Carolina 80 participants Est. completion 2015-08 1 site
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT01338298

    Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

    Not yet reported University of Maryland, Baltimore 60 participants Est. completion 2016-12 1 site
    Other conditions: Hyperprolactinemia
    View official trial listing →
  • Completed NCT NCT01354353

    A Study of Safety and Tolerability in Subjects With Schizophrenia

    Not yet reported Denovo Biopharma LLC 75 participants Est. completion 2012-03 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01386086

    Aripiprazole and Resistant Postpartum Depression

    Not yet reported London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 10 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Postpartum Depression
    View official trial listing →
  • Completed NCT NCT01411930

    Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

    Not yet reported Veterans Medical Research Foundation 15 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01416441

    Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 170 participants Est. completion 2014-03-13 80 sites Stand-alone
    Other conditions: Tourette's Disorder
    View official trial listing →
  • Completed NCT NCT01418339

    Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 135 participants Est. completion 2013-11-06 39 sites Stand-alone
    Other conditions: Tourette's Disorder
    View official trial listing →
  • Completed NCT NCT01418352

    Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 83 participants Est. completion 2014-03-12 35 sites Stand-alone
    Other conditions: Tourette's Disorder
    View official trial listing →
  • Completed NCT NCT01421342

    VA Augmentation and Switching Treatments for Improving Depression Outcomes

    Not yet reported VA Office of Research and Development 1522 participants Est. completion 2016-06 35 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01424449

    A PET Study in Healthy Volunteers

    Not yet reported GlaxoSmithKline 7 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01429831

    Aripiprazole for the Augmentation of Antidepressant Therapy

    Not yet reported Taiwan Otsuka Pharm. Co., Ltd 300 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01432444

    Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 493 participants Est. completion 2013-12 124 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01438060

    Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 232 participants Est. completion 2010-07 Stand-alone
    Other conditions: Dementia, Alzheimer Type
    View official trial listing →
  • Completed NCT NCT01446328

    Bergen Psychosis Project 2 - The Best Intro Study

    Not yet reported Haukeland University Hospital 151 participants Est. completion 2017-12 4 sites
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT01469039

    A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

    Not yet reported Alkermes, Inc. 623 participants Est. completion 2014-03 84 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT01488266

    Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder

    Not yet reported Korea University 90 participants Est. completion 2013-03 2 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01490086

    RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

    Not yet reported Reviva Pharmaceuticals 234 participants Est. completion 2013-03 15 sites
    Other conditions: Acute Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Withdrawn NCT NCT01495156

    Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

    Not yet reported Northwell Health Est. completion 2015-09 1 site Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01498770

    An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    Organon and Co 42 participants Est. completion 2017-12-21
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT01509053

    Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 30 participants Est. completion 2012-10 10 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01520350

    Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study

    Not yet reported Serge Beaulieu 2 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Bipolar Disorder, Depressive Episode
    View official trial listing →
  • Completed NCT NCT01552772

    Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 60 participants Est. completion 2012-04 12 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01556763

    Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

    Not yet reported FORUM Pharmaceuticals Inc 21 participants Est. completion 2008-08 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
    View official trial listing →
  • Completed NCT NCT01562808

    Change in Brain Metabolism and Cognitive Function by Aripiprazole

    Not yet reported Seoul National University Hospital 15 participants Est. completion 2012-01 1 site
    Other conditions: Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
    View official trial listing →
  • Completed NCT NCT01567527

    Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 731 participants Est. completion 2016-04 76 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01584765

    Rechallenge, Potential Drug Induced Liver Injury (Kaiser)

    GlaxoSmithKline 1 participants Est. completion 2013-04
    Other conditions: Drug-induced Liver Injury
    View official trial listing →
  • Terminated NCT NCT01592201

    A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug

    Not yet reported Janssen Korea, Ltd., Korea 13 participants Est. completion 2013-06 9 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01607762

    A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics

    Not yet reported Janssen Research & Development, LLC 31 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01617447

    A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 92 participants Est. completion 2015-06 5 sites Stand-alone
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT01617460

    A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 86 participants Est. completion 2016-10 5 sites Stand-alone
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT01646827

    An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 37 participants Est. completion 2013-04 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01655706

    Canadian Biomarker Integration Network for Depression Study

    Not yet reported University Health Network, Toronto 211 participants Est. completion 2017-01 6 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01660880

    Validation of Receptor Occupancy Simulation

    Seoul National University Hospital 7 participants Est. completion 2014-04 1 site
    Other conditions: Dopamine Receptor Occupancy, Medication Satisfaction, Prolactin Level, Schizophrenia
    View official trial listing →
  • Completed NCT NCT01663532

    Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 340 participants Est. completion 2013-09 49 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01683058

    Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 74 participants Est. completion 2014-02 38 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01696617

    Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

    Not yet reported Seoul National University Hospital 46 participants Est. completion 2019-02 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Status unknown NCT NCT01710163

    Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients

    Not yet reported University of Sao Paulo 50 participants Est. completion 2015-06 2 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01710709

    Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 748 participants Est. completion 2016-12 142 sites Stand-alone
    Other conditions: Bipolar I
    View official trial listing →
  • Completed NCT NCT01714011

    Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome

    Not yet reported University of Malaya 175 participants Est. completion 2011-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT01724372

    The Role of Antidepressants or Antipsychotics in Preventing Psychosis

    Not yet reported St. Luke's-Roosevelt Hospital Center Est. completion 2014-05
    Other conditions: Psychotic Disorder
    View official trial listing →
  • Completed NCT NCT01727700

    Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 133 participants Est. completion 2013-09 75 sites Stand-alone
    Other conditions: Tourette's Disorder, Tic Disorder
    View official trial listing →
  • Completed NCT NCT01727713

    Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 110 participants Est. completion 2014-09 33 sites Stand-alone
    Other conditions: Tourette's Disorder, Tic Disorder
    View official trial listing →
  • Completed NCT NCT01739127

    Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

    University of British Columbia 83 participants Est. completion 2016-02 1 site
    Metabolic syndrome Other conditions: Psychotic Disorders, Bipolar Disorder
    View official trial listing →
  • Status unknown NCT NCT01742390

    A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders

    Not yet reported Si Tianmei 120 participants Est. completion 2014-06 2 sites Stand-alone
    Other conditions: Sexual Dysfunction, Hyperprolactinemia
    View official trial listing →
  • Status unknown NCT NCT01765829

    Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

    Not yet reported Fundación Pública Andaluza Progreso y Salud 104 participants Est. completion 2015-11 17 sites
    Other conditions: Psychosis Nos/Other
    View official trial listing →
  • Completed NCT NCT01786369

    Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

    Northwell Health 106 participants Est. completion 2015-04 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01795105

    ABF Tourette's Disorder Post Marketing Surveillance Study

    Korea Otsuka Pharmaceutical Co., Ltd. 692 participants Est. completion 2015-05-29 4 sites
    Other conditions: Tourette's Disorder
    View official trial listing →
  • Completed NCT NCT01795547

    Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

    Not yet reported H. Lundbeck A/S 295 participants Est. completion 2014-09 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01813643

    A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

    Not yet reported Wei Hao 50 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Methamphetamine Dependence
    View official trial listing →
  • Terminated NCT NCT01813656

    An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

    Not yet reported Wei Hao 10 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Methamphetamine Dependence
    View official trial listing →
  • Completed NCT NCT01822730

    A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

    Not yet reported Wei Hao 120 participants Est. completion 2014-05 1 site
    Other conditions: Methamphetamine Dependence
    View official trial listing →
  • Terminated NCT NCT01844700

    1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

    Not yet reported Northwell Health 14 participants Est. completion 2014-04 1 site
    Other conditions: High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
    View official trial listing →
  • Completed NCT NCT01870999

    A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 41 participants Est. completion 2008-10 7 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01909466

    Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 141 participants Est. completion 2014-04 11 sites
    Other conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
    View official trial listing →
  • Terminated NCT NCT01913327

    Antipsychotic Effects on Brain Function in Schizophrenia

    Not yet reported University of California, San Francisco 4 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
    View official trial listing →
  • Completed NCT NCT01942148

    A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 68 participants Est. completion 2015-11 8 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01942161

    A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

    Not yet reported, Not yet reported Otsuka Pharmaceutical Co., Ltd. 106 participants Est. completion 2014-11 8 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT01942187

    A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults

    Not yet reported New York State Psychiatric Institute Est. completion 2015-12 1 site
    Other conditions: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)
    View official trial listing →
  • Completed NCT NCT01959035

    Aripiprazole Once-monthly in Patients With Schizophrenia

    Not yet reported H. Lundbeck A/S 88 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT01981811

    Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. Est. completion 2014-12 12 sites
    Other conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
    View official trial listing →
  • Completed NCT NCT02007928

    Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic

    Not yet reported Centre Hospitalier Universitaire de Nice 200 participants Est. completion 2017-07 14 sites
    Other conditions: Dissociative Disorders, Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02013232

    Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia

    Not yet reported Beijing HuiLongGuan Hospital 120 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02040883

    Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia

    Not yet reported Qingyun Yin 100 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02046564

    Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 412 participants Est. completion 2016-09 29 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT02050854

    Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

    Otsuka Pharmaceutical Development & Commercialization, Inc. 47 participants Est. completion 2014-01 5 sites
    Other conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
    View official trial listing →
  • Completed NCT NCT02054702

    Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 97 participants Est. completion 2014-07 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02069977

    Study to Evaluate the Efficacy and Safety of Aripiprazole

    Not yet reported Yoo-Sook Joung 79 participants Est. completion 2016-02 6 sites Stand-alone
    Other conditions: Autism
    View official trial listing →
  • Completed NCT NCT02087579

    Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

    Not yet reported Janssen Research & Development, LLC 305 participants Est. completion 2014-12 24 sites Stand-alone
    Other conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
    View official trial listing →
  • Completed NCT NCT02088697

    A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 50 participants Est. completion 2014-01 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02091882

    Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 30 participants Est. completion 2014-04-18 1 site Stand-alone
    Other conditions: Device Latency
    View official trial listing →
  • Terminated NCT NCT02131415

    Real Life Assessment of Abilify Maintena

    Lundbeck Canada Inc. 200 participants Est. completion 2017-02-15 17 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02137616

    Antipsychotic to Treat Psychosis Syndrome

    Not yet reported Central South University 300 participants Est. completion 2014-12 1 site
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02146547

    European Long-acting Antipsychotics in Schizophrenia Trial

    Not yet reported UMC Utrecht 536 participants Est. completion 2020-08-26 49 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02168920

    Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 150 participants Est. completion 2016-03-18 1 site Stand-alone
    Other conditions: Agitation Associated With Dementia of the Alzheimer's Type
    View official trial listing →
  • Completed NCT NCT02191358

    YouScript IMPACT Registry

    Genelex Corporation 800 participants Est. completion 2015-08 7 sites
    Other conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
    View official trial listing →
  • Completed NCT NCT02192723

    A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

    Not yet reported Beijing HuiLongGuan Hospital 550 participants Est. completion 2014-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT02213887

    Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications

    Not yet reported University of British Columbia Est. completion 2020-11-02 1 site
    Other conditions: Psychotic Disorders, Gastroesophageal Reflux
    View official trial listing →
  • Completed NCT NCT02219009

    Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 67 participants Est. completion 2015-07 6 sites Stand-alone
    Other conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
    View official trial listing →
  • Completed NCT NCT02220712

    A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 17 participants Est. completion 2015-04 5 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02237417

    Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

    Not yet reported University of Utah 47 participants Est. completion 2020-07-30 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02282085

    Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

    Not yet reported Matt Byerly 200 participants 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02297126

    A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

    Not yet reported Indiana University 4465 participants Est. completion 2019-05-03 1 site
    Other conditions: Adverse Drug Reaction
    View official trial listing →
  • Completed NCT NCT02305823

    Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

    Not yet reported Fundación Marques de Valdecilla 203 participants Est. completion 2014-05 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02320032

    An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

    Not yet reported Alkermes, Inc. 140 participants Est. completion 2016-04 16 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02334904

    Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI

    University of British Columbia 60 participants Est. completion 2016-06 1 site
    Other conditions: First-Episode Psychosis, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02339844

    Pan European Collaboration on Antipsychotic Naïve Schizophrenia II

    Not yet reported University of Copenhagen 130 participants Est. completion 2021-01 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02357849

    Fluoxetine vs Aripiprazole Comparative Trial (FACT)

    Not yet reported Northwell Health 9 participants Est. completion 2022-04-04 1 site
    Other conditions: Attenuated Psychosis Syndrome
    View official trial listing →
  • Completed NCT NCT02360319

    Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

    Not yet reported Vanguard Research Group 489 participants Est. completion 2019-03-31 39 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02374567

    Pharmacovigilance in Gerontopsychiatric Patients

    Not yet reported Hannover Medical School 407 participants Est. completion 2017-06-28 5 sites Stand-alone
    Other conditions: Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
    View official trial listing →
  • Completed NCT NCT02404532

    Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 30 participants Est. completion 2015-03 1 site
    Other conditions: Device Latency
    View official trial listing →
  • Completed NCT NCT02431702

    A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

    Not yet reported Janssen Scientific Affairs, LLC 337 participants Est. completion 2019-11-12 38 sites
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Terminated NCT NCT02435095

    Antipsychotic Induced Structural and Functional Brain Changes

    Not yet reported RWTH Aachen University 174 participants Est. completion 2020-08 11 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02435836

    A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 631 participants Est. completion 2012-12 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02439099

    Retinoic Acid Homeostasis in Neuropsychiatric Diseases

    Charite University, Berlin, Germany 200 participants Est. completion 2022-12 1 site
    Other conditions: Major Depression, Alzheimer's Disease, Alcoholism, Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02462473

    A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

    Not yet reported Janssen Research & Development, LLC 9 participants Est. completion 2016-01 3 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Terminated NCT NCT02472652

    Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

    Not yet reported Gazda, Thomas D., M.D., PC 2 participants Est. completion 2017-03-01 1 site
    Other conditions: Sexual Dysfunction
    View official trial listing →
  • Completed NCT NCT02501109

    Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers

    Not yet reported CMG Pharmaceutical Co. Ltd 36 participants Est. completion 2016-03 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02526030

    Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

    Not yet reported Fundación Marques de Valdecilla 203 participants Est. completion 2015-06 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Status unknown NCT NCT02529163

    Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms

    Not yet reported Centre for Addiction and Mental Health 24 participants Est. completion 2019-07 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Status unknown NCT NCT02532491

    Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up

    Not yet reported Fundación Marques de Valdecilla 200 participants Est. completion 2020-12 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02534363

    Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up

    Not yet reported Fundación Marques de Valdecilla 136 participants Est. completion 2013-01 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02574741

    Combination Treatment for Augmenting Language in Children With ASD

    Not yet reported University of California, Los Angeles 58 participants Est. completion 2019-12 1 site
    Other conditions: Autism Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT02582736

    Antipsychotics and Risk of Hyperglycemic Emergencies

    Canadian Network for Observational Drug Effect Studies, CNODES 725489 participants Est. completion 2012-12 1 site
    Type 2 diabetes Other conditions: Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02600741

    Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    Janssen Scientific Affairs, LLC 296 participants Est. completion 2018-07-05 34 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02630888

    Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients

    Not yet reported University of Sao Paulo 44 participants Est. completion 2020-09 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02634320

    A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

    Not yet reported Alkermes, Inc. 51 participants Est. completion 2017-07-11 18 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02634463

    Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

    Not yet reported Janssen Research & Development, LLC 81 participants Est. completion 2016-11-09 1 site
    Other conditions: Immunoassay, Antipsychotic
    View official trial listing →
  • Completed NCT NCT02636842

    A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

    Not yet reported Alkermes, Inc. 47 participants Est. completion 2016-06 6 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Status unknown NCT NCT02650102

    The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

    Not yet reported, Not yet reported Shanxi Medical University 200 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02697045

    Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch

    Not yet reported Abdi İbrahim Otsuka 23 participants Est. completion 2018-03-31 15 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02717130

    Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

    Not yet reported Florida Atlantic University 9 participants Est. completion 2017-05-25 4 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02722967

    Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 49 participants Est. completion 2016-09 4 sites Stand-alone
    Other conditions: Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT02822092

    Striatal Connectivity and Clinical Outcome in Psychosis

    Northwell Health 196 participants Est. completion 2023-12 1 site
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Terminated NCT NCT02893371

    Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

    University of New Mexico 1037352 participants Est. completion 2019-06-30 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02897167

    Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients

    Fundación Marques de Valdecilla 150 participants Est. completion 2019-03 1 site
    Other conditions: Schizophrenia, Mental Disorders, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02918370

    Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

    Not yet reported University of Texas Southwestern Medical Center 75 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Bipolar Disorder, Alcoholism, Alcohol Abuse
    View official trial listing →
  • Active, not recruiting NCT NCT02926859

    Enhancing Recovery in Early Schizophrenia

    Not yet reported Central Institute of Mental Health, Mannheim 180 participants Est. completion 2027-12 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02926976

    The Optimal Treatment for Treatment-resistant Schizophrenia

    Not yet reported Shanghai Mental Health Center 150 participants Est. completion 2019-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02949752

    Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile

    Not yet reported Institute of Mental Health, Singapore 67 participants Est. completion 2020-01-01 1 site Stand-alone
    Other conditions: Antipsychotics Weight Gain
    View official trial listing →
  • Withdrawn NCT NCT02955654

    Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder

    Not yet reported Shanghai Mental Health Center Est. completion 2018-12
    Other conditions: Obsessive-Compulsive Disorder
    View official trial listing →
  • Completed NCT NCT02960763

    Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

    Not yet reported Washington University School of Medicine 742 participants Est. completion 2021-09-01 5 sites Stand-alone
    Other conditions: Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
    View official trial listing →
  • Completed NCT NCT02977299

    Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

    Not yet reported Massachusetts General Hospital 278 participants Est. completion 2022-04-24 13 sites Stand-alone
    Other conditions: Treatment Resistant Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT03005769

    Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy

    Otsuka Pharmaceutical Europe Ltd 262 participants Est. completion 2017-07 20 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03019887

    Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

    Not yet reported Juntendo University 139 participants Est. completion 2017-01 Stand-alone
    Other conditions: Schizophrenia Relapse
    View official trial listing →
  • Status unknown NCT NCT03090503

    Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up

    Not yet reported Fundación Marques de Valdecilla 200 participants Est. completion 2021-06 1 site
    Other conditions: Schizophrenia, Psychotic Disorders, Psychosis
    View official trial listing →
  • Status unknown NCT NCT03130465

    Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

    Otsuka Pharmaceutical Europe Ltd 636 participants Est. completion 2020-01-31 67 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03130478

    Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain

    Otsuka Pharmaceutical Europe Ltd 119 participants Est. completion 2018-07-30 15 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03148509

    A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

    Not yet reported Peking University 300 participants Est. completion 2019-12-30 Stand-alone
    Other conditions: Diagnosis and Treatment of Depression
    View official trial listing →
  • Completed NCT NCT03150771

    Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 36 participants Est. completion 2018-05-02 3 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03172871

    Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia

    Not yet reported Otsuka Beijing Research Institute 436 participants Est. completion 2019-09-30 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03179787

    Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

    Otsuka Pharmaceutical Co., Ltd. 528 participants Est. completion 2020-07-06 1 site
    Other conditions: Autism
    View official trial listing →
  • Completed NCT NCT03198078

    Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 316 participants Est. completion 2023-04-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03232710

    Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

    Not yet reported Chengdu Kanghong Pharmaceutical Group Co., Ltd. 66 participants Est. completion 2018-06-30 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
  • Completed NCT NCT03238326

    Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 295 participants Est. completion 2025-04-22 57 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03285503

    PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia

    Not yet reported Otsuka Beijing Research Institute 12 participants Est. completion 2019-10-14 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03287505

    Aripiprazole IM Depot for Chinese Patients With Schizophrenia

    Not yet reported Otsuka Beijing Research Institute 24 participants Est. completion 2019-11-08 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03289026

    Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

    Not yet reported Peking University 770 participants Est. completion 2021-02-02 12 sites Stand-alone
    Other conditions: Acute Schizophrenia Episode
    View official trial listing →
  • Completed NCT NCT03342963

    Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

    Not yet reported Otsuka Pharmaceutical Co., Ltd. 74 participants Est. completion 2018-01-18 1 site Stand-alone
    Other conditions: Healthy Male Adults
    View official trial listing →
  • Completed NCT NCT03345979

    A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

    Not yet reported Alkermes, Inc. 200 participants Est. completion 2019-03-12 16 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03358277

    Aripiprazole Added on for DMDD in Youths With ADHD

    Not yet reported Tri-Service General Hospital (TSGH) 58 participants Est. completion 2017-08-12
    Other conditions: Disruptive Mood Dysregulation Disorder
    View official trial listing →
  • Completed NCT NCT03376763

    MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 201 participants Est. completion 2021-11-19 27 sites Stand-alone
    Other conditions: Schizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole
    View official trial listing →
  • Completed NCT NCT03386851

    Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder

    Korea Otsuka Pharmaceutical Co., Ltd. 1030 participants Est. completion 2021-05-25 1 site
    Other conditions: Schizophrenia, Bipolar 1 Disorder
    View official trial listing →
  • Completed NCT NCT03408873

    CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

    Not yet reported Martha Sajatovic 30 participants Est. completion 2020-05-06 1 site Stand-alone
    Other conditions: Bipolar Disorder, Medication Adherence, Medication Non Adherence
    View official trial listing →
  • Status unknown NCT NCT03423680

    A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 390 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Depression, Bipolar
    View official trial listing →
  • Active, not recruiting NCT NCT03442101

    Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

    University of Alabama at Birmingham 156 participants Est. completion 2026-12-31 1 site
    Other conditions: Psychosis
    View official trial listing →
  • Completed NCT NCT03451734

    Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients

    Central South University 2000 participants Est. completion 2021-06-30 1 site
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03485417

    Substance Misuse To Psychosis for Stimulants

    Not yet reported, Not yet reported The University of Hong Kong 165 participants Est. completion 2025-05-31 1 site
    Other conditions: Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
    View official trial listing →
  • Completed NCT NCT03487770

    Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder

    Not yet reported Otsuka Beijing Research Institute 111 participants Est. completion 2020-04-21 1 site Stand-alone
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT03487783

    Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

    Not yet reported Otsuka Beijing Research Institute 121 participants Est. completion 2020-02-14 1 site Stand-alone
    Other conditions: Tourette Syndrome
    View official trial listing →
  • Completed NCT NCT03510325

    Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

    Not yet reported Shanghai Mental Health Center 762 participants Est. completion 2023-09-27 7 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03522168

    Long-term Antipsychotic Pediatric Safety Trial

    Duke University 509 participants Est. completion 2023-11-21 37 sites
    Other conditions: Weight, Body
    View official trial listing →
  • Completed NCT NCT03557931

    A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    Not yet reported Astellas Pharma Global Development, Inc. 233 participants Est. completion 2019-10-21 27 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03568500

    A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 44 participants Est. completion 2019-09-06 5 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
    View official trial listing →
  • Terminated NCT NCT03643159

    A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 2 participants Est. completion 2018-10-17 5 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
    View official trial listing →
  • Terminated NCT NCT03661983

    Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 36 participants Est. completion 2020-06-30 42 sites Stand-alone
    Other conditions: Tourette's Disorder (TD)
    View official trial listing →
  • Completed NCT NCT03666715

    A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

    Janssen-Cilag Farmaceutica Ltda. 55 participants Est. completion 2021-05-31 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03790085

    Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

    Not yet reported Tianjin Medical University General Hospital 2700 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Schizophrenia, Major Depressive Disorder, Anxiety Disorders
    View official trial listing →
  • Completed NCT NCT03839251

    Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients

    Not yet reported Chonbuk National University Hospital 82 participants Est. completion 2020-09-30 5 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03854409

    A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 72 participants Est. completion 2020-02-20 4 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT03874494

    Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

    Not yet reported Otsuka Beijing Research Institute 371 participants Est. completion 2021-09-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03881449

    DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

    Not yet reported Durham VA Medical Center 46 participants Est. completion 2021-11 2 sites Stand-alone
    Other conditions: Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
    View official trial listing →
  • Status unknown NCT NCT03883204

    Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up

    Not yet reported Fundación Marques de Valdecilla 115 participants Est. completion 2020-12 1 site
    Other conditions: Schizophrenia, Psychotic Disorders, Psychosis
    View official trial listing →
  • Terminated NCT NCT03892889

    A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 277 participants Est. completion 2020-09-29 68 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03919994

    Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

    Alkermes, Inc. 338 participants Est. completion 2023-01-04 57 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT04030143

    A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

    Not yet reported, Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 266 participants Est. completion 2020-07-08 19 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar I Disorder
    View official trial listing →
  • Terminated NCT NCT04203056

    Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

    Not yet reported University of California, Los Angeles 15 participants Est. completion 2022-10-01 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
    View official trial listing →
  • Status unknown NCT NCT04234776

    Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression

    Not yet reported University of Sao Paulo 88 participants Est. completion 2021-04-03 1 site Stand-alone
    Other conditions: Depressive Disorder
    View official trial listing →
  • Completed NCT NCT04312503

    Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    Aziende Chimiche Riunite Angelini Francesco S.p.A 95 participants Est. completion 2022-10-31 18 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT04446234

    Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

    Not yet reported Shanghai Mental Health Center 350 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT04747314

    Treating Negative Affect in Low Back Pain Patients

    Not yet reported Ajay Wasan, MD, Msc 308 participants Est. completion 2024-12-20 3 sites
    Other conditions: Chronic Low Back Pain, Negative Affectivity
    View official trial listing →
  • Withdrawn NCT NCT04765085

    Clinical Efficacy and Change of Life Quality Through Using the Comprehensive Behavioral Intervention Treatment for Tics

    Not yet reported Children's Hospital of Fudan University Est. completion 2022-09 Stand-alone
    Other conditions: Tic Disorders
    View official trial listing →
  • Completed NCT NCT04812379

    Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)

    Otsuka Pharmaceutical Co., Ltd. 535 participants Est. completion 2024-06-21 1 site
    Other conditions: Bipolar Disorder I
    View official trial listing →
  • Completed NCT NCT04903353

    Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

    Not yet reported Vanderbilt University Medical Center 30 participants Est. completion 2025-12-01 1 site
    Other conditions: Weight Gain, Autism Spectrum Disorder, Medication Side Effect
    View official trial listing →
  • Status unknown NCT NCT04907279

    Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

    Otsuka Canada Pharmaceutical Inc. 200 participants Est. completion 2023-06 1 site
    Other conditions: Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
    View official trial listing →
  • Status unknown NCT NCT04963257

    Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 400 participants Est. completion 2024-12-31 1 site
    Other conditions: OCD
    View official trial listing →
  • Completed NCT NCT05103410

    Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy

    Not yet reported Ain Shams University 80 participants Est. completion 2023-01-10 1 site
    Other conditions: Anesthesia, Analgesia, Hysterotomy
    View official trial listing →
  • Completed NCT NCT05169268

    Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

    The University of Hong Kong 6 participants Est. completion 2026-01-31 1 site
    Other conditions: Schizophrenia and Related Disorders, Anxiety Depression
    View official trial listing →
  • Completed NCT NCT05322031

    The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

    Not yet reported Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 15 participants Est. completion 2024-11-30 1 site Stand-alone
    Other conditions: Schizophrenia, Myelin Degeneration, Cognition Disorder
    View official trial listing →
  • Withdrawn NCT NCT05361993

    Efficacy of Biofeedback in the Treatment of Tic Disorder

    Not yet reported Children's Hospital of Fudan University Est. completion 2024-12-31 1 site
    Other conditions: Tic Disorders
    View official trial listing →
  • Status unknown NCT NCT05389046

    Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

    Not yet reported Peking University 252 participants Est. completion 2025-12 3 sites Stand-alone
    Other conditions: Outpatients / Inpatients With Depression
    View official trial listing →
  • Completed NCT NCT05402111

    A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 31 participants Est. completion 2023-09-27 7 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT05473741

    Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

    Centre for Addiction and Mental Health 51 participants Est. completion 2025-10-27 1 site
    Other conditions: Schizophrenia, Schizophrenia Relapse
    View official trial listing →
  • Completed NCT NCT05531591

    RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

    Not yet reported Centre for Addiction and Mental Health 87 participants Est. completion 2024-07-31 4 sites Stand-alone
    Other conditions: Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
    View official trial listing →
  • Completed NCT NCT05532254

    Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

    Not yet reported Future University in Egypt 31 participants Est. completion 2021-03-11 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT05542264

    A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 19 participants Est. completion 2024-02-12 4 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Not yet recruiting NCT NCT05545891

    Aripiprazole in Body Focused Repetitive Behaviors

    Not yet reported University of Chicago 100 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania
    View official trial listing →
  • Withdrawn NCT NCT05554627

    VA Aripiprazole vs Esketamine for Treatment Resistant Depression

    Not yet reported VA Office of Research and Development Est. completion 2023-10-27 26 sites
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Status unknown NCT NCT05646264

    A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia

    Not yet reported Shanghai Mental Health Center 220 participants Est. completion 2023-08-01 1 site Stand-alone
    Other conditions: Schizophrenia, Negative Symptoms in Schizophrenia
    View official trial listing →
  • Terminated NCT NCT05662306

    C-Cog in Early Course Schizophrenia Study

    Not yet reported University of Miami 1 participants Est. completion 2025-03-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT05686772

    Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis

    Laval University 520 participants Est. completion 2023-05-01 2 sites
    Other conditions: Gambling Disorder, Psychotic Disorders
    View official trial listing →
  • Terminated NCT NCT05741502

    An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

    Not yet reported Ohio State University 5 participants Est. completion 2026-01-23 1 site
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT05766540

    Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 60 participants Est. completion 2023-12-31 Stand-alone
    Other conditions: Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia
    View official trial listing →
  • Completed NCT NCT05804721

    Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

    Not yet reported Genuine Research Center, Egypt 29 participants Est. completion 2022-12-19 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT05868720

    EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 42 participants Est. completion 2025-03-02 Stand-alone
    Other conditions: The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
    View official trial listing →
  • Status unknown NCT NCT05889234

    Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study

    First Affiliated Hospital of Chongqing Medical University 180 participants Est. completion 2026-01-01 1 site
    Other conditions: Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy
    View official trial listing →
  • Completed NCT NCT05974241

    Irritability in Children With ADHD and Emotion Dysregulation

    Not yet reported Tri-Service General Hospital (TSGH) 36 participants Est. completion 2022-04-07 1 site Stand-alone
    Other conditions: Irritable Mood, ADHD
    View official trial listing →
  • Completed NCT NCT06040944

    Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients

    Fayoum University 64 participants Est. completion 2022-11-01 1 site
    Other conditions: Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases
    View official trial listing →
  • Status unknown NCT NCT06060886

    Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

    Not yet reported Consorcio Centro de Investigación Biomédica en Red (CIBER) 244 participants Est. completion 2025-12-31 Stand-alone
    MASLD Other conditions: Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders, Diabetes, Psychosis
    View official trial listing →
  • Status unknown NCT NCT06128408

    The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset

    Peking University 300 participants Est. completion 2024-10-13
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Completed NCT NCT06236451

    Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 60 participants Est. completion 2025-11-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT06372210

    A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 54 participants Est. completion 2023-07-19 1 site Stand-alone
    Other conditions: Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
    View official trial listing →
  • Status unknown NCT NCT06373770

    Effects of Ayres Sensory Integration Therapy Versus Conservative Treatment in Autism Spectrum

    Not yet reported Superior University 30 participants Est. completion 2024-09-30 1 site
    Other conditions: Autism Spectrum Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT06433635

    Sequential Multiple Assignment Randomized Trial for Bipolar Depression

    Not yet reported Massachusetts General Hospital 2726 participants Est. completion 2030-02-28 18 sites Stand-alone
    Other conditions: Bipolar I Disorder, Depression
    View official trial listing →
  • Status unknown NCT NCT06501339

    Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 40 participants Est. completion 2026-03-31
    Other conditions: Clozapine Resistant Schizophrenia
    View official trial listing →
  • Not yet recruiting NCT NCT06589817

    A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

    Not yet reported Chengdu Kanghong Pharmaceutical Group Co., Ltd. 376 participants Est. completion 2026-12 Stand-alone
    Other conditions: Acute Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT06590298

    Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females

    Not yet reported Universiti Putra Malaysia 600 participants Est. completion 2025-04-10 Stand-alone
    Metabolic syndrome Other conditions: Psychosis, Weight Gain
    View official trial listing →
  • Active, not recruiting NCT NCT06799559

    Study on the Efficacy and Safety of QLM1016 in Schizophrenia

    Not yet reported Qilu Pharmaceutical Co., Ltd. 402 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Active, not recruiting NCT NCT06937476

    Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

    Not yet reported Central South University 108 participants Est. completion 2026-07-16 1 site Stand-alone
    Other conditions: Major Depressive Disorder (MDD), Rumination
    View official trial listing →
  • Not yet recruiting NCT NCT07011693

    Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)

    Not yet reported Xinyu Zhou 400 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Major Depressive Disorder (MDD)
    View official trial listing →
  • Not yet recruiting NCT NCT07024303

    Measurement of Treatment Effects

    Not yet reported Matthew J O'Brien, PhD, BCBA-D 20 participants Est. completion 2027-12-31 Stand-alone
    Other conditions: Challenging Behavior, Autism Spectrum Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT07047651

    Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

    Not yet reported Dr. Stavroula Rakitzi 84 participants Est. completion 2027-12-20 1 site Stand-alone
    Other conditions: Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07153406

    Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

    Not yet reported Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 220 participants Est. completion 2029-01-15 9 sites
    Other conditions: Depressive Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07547384

    Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.

    Not yet reported CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 116 participants Est. completion 2027-11-05 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT07550387

    A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 363 participants Est. completion 2026-01-19 1 site
    Other conditions: SCHIZOPHRENIA 1 (Disorder)
    View official trial listing →
  • Not yet recruiting NCT NCT07570875

    Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

    Not yet reported University of Alabama at Birmingham 100 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07703956

    Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

    Not yet reported Vigonvita Life Sciences 500 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Not yet recruiting NCT NCT07714213

    Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)

    Not yet reported Christiana Franke 138 participants Est. completion 2028-12-31 1 site
    Other conditions: Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
    View official trial listing →
  • Not yet recruiting NCT NCT07810738

    The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

    Not yet reported Washington University School of Medicine 300 participants Est. completion 2029-09-15 3 sites Stand-alone
    Other conditions: Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
    View official trial listing →
  • Completed NCT NCT07834112

    Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder

    Dong-Wook Kim 155 participants Est. completion 2025-12-31 1 site
    Other conditions: Bipolar Disorder (BD)
    View official trial listing →
  • Completed NCT NCT07843056

    A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

    Not yet reported EMS 121 participants Est. completion 2026-03-23 1 site
    Other conditions: Schizophenia Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07911787

    Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 476 participants Est. completion 2029-02-07 1 site
    Other conditions: SCHIZOPHRENIA 1 (Disorder)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Aripiprazole, Abilify, BMS-337039

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.